|Day Low/High||8.88 / 10.09|
|52 Wk Low/High||3.55 / 12.44|
Markets continue to trade in a very narrow range this Friday, commentary on the Daily Diary is certainly more active than equities today! Most major indices remain slightly down as they have been pretty much since the opening bell. The Dow has just ...
Markets have not changed much since our last update 90 minutes ago. Indices slightly down across the board in pretty listless trading so far. Markets look set to close out with minor losses for the week this Friday. Biotech continues to recoup some ...
It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...
The inconsistency makes stock picking difficult, but there are buying opportunities because of it.
We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.
Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.
The sector decisively has pushed through upward resistance levels in place for many months.
A look at how lawsuits and FDA changes could impact the industry.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
This biopharma company's Relistor drug should send revenues sharply higher this year.
This biopharma company's Relistor drug should send revenues sharply higher next year.
Shares of the drugmaker were falling on news that U.S. regulators have rejected its Heplisav-B application
U.S. stocks fluctuate as Wall Street picks apart the likely policies of President-elect Donald Trump.
Here are three recent examples of how the patient can profit.
These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
The markets look based on the futures like they're heading for slight upwardly tilt in opening trading. Oil is touching $41 a barrel -- its best level of the year even as Russia's central bank is calling crude's recent rally "unsustainable." Of cour...
I am starting to get more confident that the small caps are ready to bounce.